Additionally, treatment with an anti-CD70 antibody ameliorated T-cell-induced secretion of immunoglobulin by B cells in vitro, where T cells were harvested from patients with systemic lupus ...

MDX-1203, the company's first clinical antibody conjugate candidate, is a human anti-CD70 mAb linked to a prodrug form of CC-1065, an alkylating agent first isolated from Streptomyces zelensis ...

Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and ...

Several antibody–drug conjugates (ADCs), using different ... Other ADCs directed against other B-cell lineage antigens, including CD22, CD19 and CD70, are currently in Phase I/Phase II clinical ...

Several antibody–drug conjugates (ADCs), using different ... Other ADCs directed against other B-cell lineage antigens, including CD22, CD19 and CD70, are currently in Phase I/Phase II clinical ...

The proceeds from the Series A extension will fund the Phase 2 OV-AML-1231 trial of cusatuzumab, a novel, first-in-class high-affinity monoclonal anti-CD70 antibody, in combination with venetoclax ...